The Use of Low Molecular Weight Heparin in Hemodiafiltration

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low molecular weight heparin (LMWH) is injected in the dialysis circuit at the start of the session. In the present study we compare 3 different methods of injection of LMWH: parameters of dialysis efficiency and clotting are measured. The study lasts 3 sessions for each patient.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Chronic Hemodialysis Without Systemic Heparinization : a Randomized Study

NCT00473109

Contra-Indication to the Use of Low Molecular Weight Heparin

COMPLETED PHASE3

Anticoagulation in Chronic Hemodialysis Patients Versus Hemodialyzer Fiber Patency, Bleedings and Quality of Life

NCT05365542

Blood Coagulation

COMPLETED

Coupling Between Clotting Characteristics in Chronic Hemodialysis Patients and the Hemodialyzer Patency

NCT05440201

Bleeding Coagulation

COMPLETED NA

Low Molecular Weight Heparin for Hemodialysis Anticoagulation

NCT01356615

End Stage Renal Failure on Dialysis

COMPLETED NA

Citrate Anticoagulation vs. Heparin-Coated Dialyzers

NCT00395824

Dialysis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Injection of LMWH at the start of the hemodiafiltration session, at the inlet bloodline

Group Type EXPERIMENTAL

At start of the session, at the inlet line

Intervention Type PROCEDURE

Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

2

Injection of LMWH 5 minutes after the start of the hemodiafiltration session, at the inlet bloodline

Group Type EXPERIMENTAL

5 minutes after the start of the session, at the inlet line

Intervention Type PROCEDURE

Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

3

Injection of LMWH at the start of the hemodiafiltration session, at the outline bloodline

Group Type EXPERIMENTAL

At the start of the session, at the outlet line

Intervention Type PROCEDURE

Injection of LMWH at the outlet line, at the start of the hemodiafiltration session

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

At start of the session, at the inlet line

Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

Intervention Type PROCEDURE

5 minutes after the start of the session, at the inlet line

Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

Intervention Type PROCEDURE

At the start of the session, at the outlet line

Injection of LMWH at the outlet line, at the start of the hemodiafiltration session

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic kidney disease stade V treated with hemodiafiltration
* age \>18 year
* Hematocrit \> 30%

Exclusion Criteria

* treatment with vitamin K antagonists
* treatment with other anti-coagulants or heparin besides the heparin used during dialysis
* active bleeding, infection or malignancy
* heparin associated allergy
* hepatic failure
* trombocytopenia \< 120.000/µl

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No